U.S. Women Health Laboratory Testing Market Size, Trends & Forecast to 2030

Market Research Report

A quick peek into the report

1.1   U.S. Market Outlook
1.1.1   Product Definition
1.1.2   Inclusion and Exclusion Criteria
1.2   Business Dynamics
1.2.1   Impact Analysis
1.2.2   Business Drivers
1.2.2.1   Increase in the Prevalence of Infectious Diseases and Cancer in Women Leading to Increased Demand for Laboratory Diagnostics
1.2.2.2   Rising Awareness Regarding Women Health-Related Tests
1.2.2.3   Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies
1.2.2.4   Upsurge in Reproductive Health Problems Leading to Increased Demand for Laboratory Testing in Women
1.2.3   Business Restraints
1.2.3.1   Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.
1.2.3.2   Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.
1.2.4   Business Opportunities
1.2.4.1   Advancement in Diagnostic Technologies, including Applications of Genetic Testing in Women's Health
1.2.4.2   Healthcare Disparities in the Rural Counties of the U.S.
1.2.4.3   Gap in Healthcare for Women of Reproductive Age with Psychological Distress
1.2.4.4   Significant Number of Mergers and Acquisitions by Companies to Attain a Better Market Share

2.1   Overview
2.2   Breast Cancer
2.2.1   Epidemiology
2.2.2   Testing Market
2.2.3   Testing Market (by Region)
2.2.3.1   Northeast Region (by State)
2.2.3.2   Midwest Region (by State)
2.2.3.3   South Region (by State)
2.2.3.4   West Region (by State)
2.3   Cervical Cancer
2.3.1   Epidemiology
2.3.2   Testing Market
2.3.3   Testing Market (by Region)
2.3.3.1   Northeast Region (by State)
2.3.3.2   Midwest Region (by State)
2.3.3.3   South Region (by State)
2.3.3.4   West Region (by State)
2.4   Ovarian Cancer
2.4.1   Epidemiology
2.4.2   Testing Market
2.4.3   Testing Market (by Region)
2.4.3.1   Northeast Region (by State)
2.4.3.2   Midwest Region (by State)
2.4.3.3   South Region (by State)
2.4.3.4   West Region (by State)

3.1   Overview
3.1.1   Testing Market
3.1.2   Testing Market (by Region)
3.1.2.1   Northeast Region (by State)
3.1.2.2   Midwest Region (by State)
3.1.2.3   South Region (by State)
3.1.2.4   West Region (by State)

4.1   Overview
4.2   Non-Invasive Prenatal Testing (NIPT)
4.2.1   Testing Market
4.2.2   Testing Market (by Region)
4.2.2.1   Northeast Region (by State)
4.2.2.2   Midwest Region (by State)
4.2.2.3   South Region (by State)
4.2.2.4   West Region (by State)
4.3   Maternal Serum Screening (MSS)
4.3.1   Testing Market
4.3.2   Testing Market (by Region)
4.3.2.1   Northeast Region (by State)
4.3.2.2   Midwest Region (by State)
4.3.2.3   South Region (by State)
4.3.2.4   West Region (by State)
4.4   Prenatal Diagnostic Testing
4.4.1   Testing Market
4.4.2   Testing Market (by Region)
4.4.2.1   Northeast Region (by State)
4.4.2.2   Midwest Region (by State)
4.4.2.3   South Region (by State)
4.4.2.4   West Region (by State)

5.1   Overview
5.2   Pregnancy and Ovulation Testing
5.2.1   Testing Market
5.2.2   Testing Market (by Region)
5.2.2.1   Northeast Region (by State)
5.2.2.2   Midwest Region (by State)
5.2.2.3   South Region (by State)
5.2.2.4   West Region (by State)
5.3   HPV Testing
5.3.1   Testing Market
5.3.2   Testing Market (by Region)
5.3.2.1   Northeast Region (by State)
5.3.2.2   Midwest Region (by State)
5.3.2.3   South Region (by State)
5.3.2.4   West Region (by State)
5.4   PAP Smear Testing
5.4.1   Testing Market
5.4.2   Testing Market (by Region)
5.4.2.1   Northeast Region (by State)
5.4.2.2   Midwest Region (by State)
5.4.2.3   South Region (by State)
5.4.2.4   West Region (by State)
5.5   HIV Testing
5.5.1   Testing Market
5.5.2   Testing Market (by Region)
5.5.2.1   Northeast Region (by State)
5.5.2.2   Midwest Region (by State)
5.5.2.3   South Region (by State)
5.5.2.4   West Region (by State)
5.6   CT/NG Testing
5.6.1   Testing Market
5.6.2   Testing Market (by Region)
5.6.2.1   Northeast Region (by State)
5.6.2.2   Midwest Region (by State)
5.6.2.3   South Region (by State)
5.6.2.4   West Region (by State)
5.7   Preimplantation Genetic Testing (PGT)
5.7.1   Testing Market
5.7.2   Testing Market (by Region)
5.7.2.1   Northeast Region (by State)
5.7.2.2   Midwest Region (by State)
5.7.2.3   South Region (by State)
5.7.2.4   West Region (by State)
5.8   Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia)
5.8.1   Testing Market
5.8.2   Testing Market (by Region)
5.8.2.1   Northeast Region (by State)
5.8.2.2   Midwest Region (by State)
5.8.2.3   South Region (by State)
5.8.2.4   West Region (by State)
5.9   Herpes Simplex Virus (HSV)
5.9.1   Testing Market
5.9.2   Testing Market (by Region)
5.9.2.1   Northeast Region (by State)
5.9.2.2   Midwest Region (by State)
5.9.2.3   South Region (by State)
5.9.2.4   West Region (by State)
5.10 Hepatitis
5.10.1   Testing Market
5.10.2   Testing Market (by Region)
5.10.2.1   Northeast Region (by State)
5.10.2.2   Midwest Region (by State)
5.10.2.3   South Region (by State)
5.10.2.4   West Region (by State)
5.11   Vaginal Infections
5.11.1   Testing Market
5.11.2   Testing Market (by Region)
5.11.2.1   Northeast Region (by State)
5.11.2.2   Midwest Region (by State)
5.11.2.3   South Region (by State)
5.11.2.4   West Region (by State)

6.1   Overview
6.1.1   Testing Market (by Region)
6.1.1.1   Northeast Region (by State)
6.1.1.2   Midwest Region (by State)
6.1.1.3   South Region (by State)
6.1.1.4   West Region (by State)

Table 1:   Key Questions Answered in the Report
Table 2:   U.S. Women Health Laboratory Testing Market, Approach Note
Table 3:   Cervical Cancer Market, Approach Note
Table 4:   Carrier Screening Market, Approach Note
Table 5:   Non-Invasive Prenatal Testing Market, Approach Note
Table 6:   HPV Testing Market, Approach Note
Table 7:   PAP Smear Testing Market, Approach Note
Table 8:   Sexually Transmitted Infections Market, Approach Note
Table 9:   Vaginal Infections Market, Approach Note
Table 10:   HRSA-Supported Women's Preventive Services Guidelines: Current and Updated Guidelines
Table 11:   Estimated Down Syndrome Birth Prevalence Per 1,000 Births at Different Maternal Ages

Figure 1:   Percentage of Women with Two or More Chronic Conditions, Aged 18-64 Years (by Country)
Figure 2:   U.S. Women Health Laboratory Testing Market, $Billion, 2021-2030
Figure 3:   U.S. Women Health Laboratory Testing Market (by Test Type), $Billion, 2021 and 2030
Figure 4:   U.S. Women Health Laboratory Testing Market (by Region), $Billion, 2021-2030
Figure 5:   U.S. Women Health Laboratory Testing Market, Impact Analysis
Figure 6:   U.S. Women Health Laboratory Testing Market, Key Development Analysis, January 2019-October 2022
Figure 7:   U.S. Women Health Laboratory Testing Market Segmentation
Figure 8:   U.S. Women Health Laboratory Testing Market: Research Methodology
Figure 9:   Primary Research Sources
Figure 10:   Secondary Research
Figure 11:   Data Triangulation
Figure 12:   Assumptions and Limitations
Figure 13:   U.S. Women Laboratory Testing Market, Impact Analysis
Figure 14:   Gonorrhea and Chlamydia: Rates of Reported Cases by Age Group in Women, 2020
Figure 15:   Estimated Incidence and Mortality of Cancer in Women in the U.S. (2020, 2025, 2030, 2035, and 2040)
Figure 16:   Rate of Miscarriages with Increasing Maternal Age
Figure 17:   U.S. Fertility Rates (by Total Births Per Women), 1960-2020
Figure 18:   U.S. Women Health Laboratory Testing Market (by Hereditary Cancer)
Figure 19:   Incidence and Mortality of Breast Cancer in the U.S. (2020, 2025, 2030, 2035, and 2040)
Figure 20:   Rate of New Breast Cancer Cases in the U.S. Per 100,000 Women Population (by State)
Figure 21:   U.S. Breast Cancer Market, $Million, 2021-2030
Figure 22:   U.S. Breast Cancer Market (by Region), TAM, $Million, 2021-2030
Figure 23:   U.S. Breast Cancer Market (by Region), SAM, $Million, 2021-2030
Figure 24:   U.S. Breast Cancer Market (by Region), SOM, $Million, 2021-2030
Figure 25:   Northeast Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
Figure 26:   Northeast Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
Figure 27:   Northeast Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
Figure 28:   Midwest Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
Figure 29:   Midwest Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
Figure 30:   Midwest Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
Figure 31:   South Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
Figure 32:   South Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
Figure 33:   South Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
Figure 34:   West Region Breast Cancer Market (by State), TAM, $Million, 2021-2030
Figure 35:   West Region Breast Cancer Market (by State), SAM, $Million, 2021-2030
Figure 36:   West Region Breast Cancer Market (by State), SOM, $Million, 2021-2030
Figure 37:   Estimated Incidence and Mortality of Cervical Cancer in the U.S. (2020, 2025, 2030, 2035, and 2040)
Figure 38:   Rate of New Cervical Cancer Cases in the U.S. Per 100,000 Women Population (by State), 2019
Figure 39:   U.S. Cervical Cancer Market, $Million, 2021-2030
Figure 40:   U.S. Cervical Cancer Market (by Region), TAM, $Million, 2021-2030
Figure 41:   U.S. Cervical Cancer Market (by Region), SAM, $Million, 2021-2030
Figure 42:   U.S. Cervical Cancer Market (by Region), SOM, $Million, 2021-2030
Figure 43:   Northeast Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
Figure 44:   Northeast Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
Figure 45:   Northeast Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
Figure 46:   Midwest Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
Figure 47:   Midwest Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
Figure 48:   Midwest Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
Figure 49:   South Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
Figure 50:   South Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
Figure 51:   South Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
Figure 52:   West Region Cervical Cancer Market (by State), TAM, $Million, 2021-2030
Figure 53:   South Region Cervical Cancer Market (by State), SAM, $Million, 2021-2030
Figure 54:   South Region Cervical Cancer Market (by State), SOM, $Million, 2021-2030
Figure 55:   Incidence and Mortality of Ovarian Cancer in the U.S. (2020, 2025, 2030, 2035, and 2040)
Figure 56:   Ovarian Cancer Cases (by State), 2019
Figure 57:   U.S. Ovarian Cancer Market, $Million, 2021-2030
Figure 58:   U.S. Ovarian Cancer Market (by Region), TAM, $Million, 2021-2030
Figure 59:   U.S. Ovarian Cancer Market (by Region), SAM, $Million, 2021-2030
Figure 60:   U.S. Ovarian Cancer Market (by Region), SOM, $Million, 2021-2030
Figure 61:   Northeast Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
Figure 62:   Northeast Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
Figure 63:   Northeast Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
Figure 64:   Midwest Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
Figure 65:   Midwest Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
Figure 66:   Midwest Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
Figure 67:   South Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
Figure 68:   South Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
Figure 69:   South Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
Figure 70:   West Region Ovarian Cancer Market (by State), TAM, $Million, 2021-2030
Figure 71:   West Region Ovarian Cancer Market (by State), SAM, $Million, 2021-2030
Figure 72:   West Region Ovarian Cancer Market (by State), SOM, $Million, 2021-2030
Figure 73:   U.S. Carrier Screening Market, $Million, 2021-2030
Figure 74:   U.S. Carrier Screening Market (by Region), TAM, $Million, 2021-2030
Figure 75:   U.S. Carrier Screening Market (by Region), SAM, $Million, 2021-2030
Figure 76:   U.S. Carrier Screening Market (by Region), SOM, $Million, 2021-2030
Figure 77:   Northeast Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
Figure 78:   Northeast Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
Figure 79:   Northeast Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
Figure 80:   Midwest Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
Figure 81:   Midwest Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
Figure 82:   Midwest Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
Figure 83:   South Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
Figure 84:   South Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
Figure 85:   South Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
Figure 86:   West Region Carrier Screening Market (by State), TAM, $Million, 2021-2030
Figure 87:   West Region Carrier Screening Market (by State), SAM, $Million, 2021-2030
Figure 88:   West Region Carrier Screening Market (by State), SOM, $Million, 2021-2030
Figure 89:   U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)
Figure 90:   U.S. Non-Invasive Prenatal Testing Market, $Million, 2021-2030
Figure 91:   U.S. Non-Invasive Prenatal Testing Market (by Region), TAM, $Million, 2021-2030
Figure 92:   U.S. Non-Invasive Prenatal Testing Market (by Region), SAM, $Million, 2021-2030
Figure 93:   U.S. Non-Invasive Prenatal Testing Market (by Region), SOM, $Million, 2021-2030
Figure 94:   Northeast Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
Figure 95:   Northeast Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
Figure 96:   Northeast Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
Figure 97:   Midwest Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
Figure 98:   Midwest Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
Figure 99:   Midwest Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
Figure 100:   South Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
Figure 101:   South Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
Figure 102:   South Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
Figure 103:   West Region Non-Invasive Prenatal Testing Market (by State), TAM, $Million, 2021-2030
Figure 104:   West Region Non-Invasive Prenatal Testing Market (by State), SAM, $Million, 2021-2030
Figure 105:   West Region Non-Invasive Prenatal Testing Market (by State), SOM, $Million, 2021-2030
Figure 106:   U.S. Maternal Serum Screening Market, $Million, 2021-2030
Figure 107:   U.S. Maternal Serum Screening Market (by Region), TAM, $Million, 2021-2030
Figure 108:   U.S. Maternal Serum Screening (by Region), SAM, $Million, 2021-2030
Figure 109:   U.S. Maternal Serum Screening Market (by Region), SOM, $Million, 2021-2030
Figure 110:   Northeast Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
Figure 111:   Northeast Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
Figure 112:   Northeast Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
Figure 113:   Midwest Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
Figure 114:   Midwest Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
Figure 115:   Midwest Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
Figure 116:   South Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
Figure 117:   South Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
Figure 118:   South Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
Figure 119:   West Region Maternal Serum Screening Market (by State), TAM, $Million, 2021-2030
Figure 120:   West Region Maternal Serum Screening Market (by State), SAM, $Million, 2021-2030
Figure 121:   West Region Maternal Serum Screening Market (by State), SOM, $Million, 2021-2030
Figure 122:   U.S. Prenatal Diagnostic Testing Market, $Million, 2021-2030
Figure 123:   U.S. Prenatal Diagnostic Testing Market (by Region), TAM, $Million, 2021-2030
Figure 124:   U.S. Prenatal Diagnostic Testing Market (by Region), SAM, $Million, 2021-2030
Figure 125:   U.S. Prenatal Diagnostic Testing Market (by Region), SOM, $Million, 2021-2030
Figure 126:   Northeast Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
Figure 127:   Northeast Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
Figure 128:   Northeast Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
Figure 129:   Midwest Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
Figure 130:   Midwest Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
Figure 131:   Midwest Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
Figure 132:   South Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
Figure 133:   South Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
Figure 134:   South Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
Figure 135:   West Region Prenatal Diagnostic Testing Market (by State), TAM, $Million, 2021-2030
Figure 136:   West Region Prenatal Diagnostic Testing Market (by State), SAM, $Million, 2021-2030
Figure 137:   West Region Prenatal Diagnostic Testing Market (by State), SOM, $Million, 2021-2030
Figure 138:   U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)
Figure 139:   U.S. Pregnancy and Ovulation Testing Market, $Million, 2021-2030
Figure 140:   U.S. Pregnancy and Ovulation Testing Market (by Region), TAM, $Million, 2021-2030
Figure 141:   U.S. Pregnancy and Ovulation Testing Market (by Region), SAM, $Million, 2021-2030
Figure 142:   U.S. Pregnancy and Ovulation Testing Market (by Region), SOM, $Million, 2021-2030
Figure 143:   Northeast Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
Figure 144:   Northeast Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
Figure 145:   Northeast Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
Figure 146:   Midwest Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
Figure 147:   Midwest Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
Figure 148:   Midwest Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
Figure 149:   South Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
Figure 150:   South Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
Figure 151:   South Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
Figure 152:   West Region Pregnancy and Ovulation Testing Market (by State), TAM, $Million, 2021-2030
Figure 153:   West Region Pregnancy and Ovulation Testing Market (by State), SAM, $Million, 2021-2030
Figure 154:   West Region Pregnancy and Ovulation Testing Market (by State), SOM, $Million, 2021-2030
Figure 155:   U.S. HPV Testing Market, $Million, 2021-2030
Figure 156:   U.S. HPV Testing Market (by Region), TAM, $Million, 2021-2030
Figure 157:   U.S. HPV Testing Market (by Region), SAM, $Million, 2021-2030
Figure 158:   U.S. HPV Testing Market (by Region), SOM, $Million, 2021-2030
Figure 159:   Northeast Region HPV Testing Market (by State), TAM, $Million, 2021-2030
Figure 160:   Northeast Region HPV Testing Market (by State), SAM, $Million, 2021-2030
Figure 161:   Northeast Region HPV Testing Market (by State), SOM, $Million, 2021-2030
Figure 162:   Midwest Region HPV Testing Market (by State), TAM, $Million, 2021-2030
Figure 163:   Midwest Region HPV Testing Market (by State), SAM, $Million, 2021-2030
Figure 164:   Midwest Region HPV Testing Market (by State), SOM, $Million, 2021-2030
Figure 165:   South Region HPV Testing Market (by State), TAM, $Million, 2021-2030
Figure 166:   South Region HPV Testing Market (by State), SAM, $Million, 2021-2030
Figure 167:   South Region HPV Testing Market (by State), SOM, $Million, 2021-2030
Figure 168:   West Region HPV Testing Market (by State), TAM, $Million, 2021-2030
Figure 169:   West Region HPV Testing Market (by State), SAM, $Million, 2021-2030
Figure 170:   West Region HPV Testing Market (by State), SOM, $Million, 2021-2030
Figure 171:   U.S. PAP Smear Testing Market, $Million, 2021-2030
Figure 172:   U.S. PAP Smear Testing Market (by Region), TAM, $Million, 2021-2030
Figure 173:   U.S. PAP Smear Testing Market (by Region), SAM, $Million, 2021-2030
Figure 174:   U.S. PAP Smear Testing Market (by Region), SOM, $Million, 2021-2030
Figure 175:   Northeast Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
Figure 176:   Northeast Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
Figure 177:   Northeast Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
Figure 178:   Midwest Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
Figure 179:   Midwest Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
Figure 180:   Midwest Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
Figure 181:   South Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
Figure 182:   South Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
Figure 183:   South Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
Figure 184:   West Region PAP Smear Testing (by State), TAM, $Million, 2021-2030
Figure 185:   West Region PAP Smear Testing (by State), SAM, $Million, 2021-2030
Figure 186:   West Region PAP Smear Testing (by State), SOM, $Million, 2021-2030
Figure 187:   U.S. HIV Testing Market, $Million, 2021-2030
Figure 188:   U.S. HIV Testing Market (by Region), TAM, $Million, 2021-2030
Figure 189:   U.S. HIV Testing Market (by Region), SAM, $Million, 2021-2030
Figure 190:   U.S. HIV Testing Market (by Region), SOM, $Million, 2021-2030
Figure 191:   Northeast Region HIV Testing Market (by State), TAM, $Million, 2021-2030
Figure 192:   Northeast Region HIV Testing Market (by State), SAM, $Million, 2021-2030
Figure 193:   Northeast Region HIV Testing Market (by State), SOM, $Million, 2021-2030
Figure 194:   Midwest Region HIV Testing Market (by State), TAM, $Million, 2021-2030
Figure 195:   Midwest Region HIV Testing Market (by State), SAM, $Million, 2021-2030
Figure 196:   Midwest Region HIV Testing Market (by State), SOM, $Million, 2021-2030
Figure 197:   South Region HIV Testing Market (by State), TAM, $Million, 2021-2030
Figure 198:   South Region HIV Testing Market (by State), SAM, $Million, 2021-2030
Figure 199:   South Region HIV Testing Market (by State), SOM, $Million, 2021-2030
Figure 200:   West Region HIV Testing Market (by State), TAM, $Million, 2021-2030
Figure 201:   West Region HIV Testing Market (by State), SAM, $Million, 2021-2030
Figure 202:   West Region HIV Testing Market (by State), SOM, $Million, 2021-2030
Figure 203:   U.S. CT/NG Testing Market, $Million, 2021-2030
Figure 204:   U.S. CT/NG Testing Market (by Region), TAM, $Million, 2021-2030
Figure 205:   U.S. CT/NG Testing Market (by Region), SAM, $Million, 2021-2030
Figure 206:   U.S. CT/NG Testing Market (by Region), SOM, $Million, 2021-2030
Figure 207:   Northeast Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
Figure 208:   Northeast Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
Figure 209:   Northeast Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
Figure 210:   Midwest Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
Figure 211:   Midwest Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
Figure 212:   Midwest Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
Figure 213:   South Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
Figure 214:   South Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
Figure 215:   South Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
Figure 216:   West Region CT/NG Testing Market (by State), TAM, $Million, 2021-2030
Figure 217:   West Region CT/NG Testing Market (by State), SAM, $Million, 2021-2030
Figure 218:   West Region CT/NG Testing Market (by State), SOM, $Million, 2021-2030
Figure 219:   U.S. Preimplantation Genetic Testing Market, $Million, 2021-2030
Figure 220:   U.S. Preimplantation Genetic Testing Market (by Region), TAM, $Million, 2021-2030
Figure 221:   U.S. Preimplantation Genetic Testing Market (by Region), SAM, $Million, 2021-2030
Figure 222:   U.S. Preimplantation Genetic Testing (by Region), SOM, $Million, 2021-2030
Figure 223:   Northeast Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
Figure 224:   Northeast Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
Figure 225:   Northeast Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
Figure 226:   Midwest Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
Figure 227:   Midwest Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
Figure 228:   Midwest Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
Figure 229:   South Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
Figure 230:   South Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
Figure 231:   South Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
Figure 232:   West Region Preimplantation Genetic Testing Market (by State), TAM, $Million, 2021-2030
Figure 233:   West Region Preimplantation Genetic Testing Market (by State), SAM, $Million, 2021-2030
Figure 234:   West Region Preimplantation Genetic Testing Market (by State), SOM, $Million, 2021-2030
Figure 235:   U.S. Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market, $Million, 2021-2030
Figure 236:   U.S. Sexually Transmitted Infection (Syphilis, Gonorrhea, Chlamydia) Market (by Region), TAM, $Million, 2021-2030
Figure 237:   U.S. Sexually Transmitted Infection (Syphilis, Gonorrhea, Chlamydia) Market (by Region), SAM, $Million, 2021-2030
Figure 238:   U.S. Sexually Transmitted Infection (Syphilis, Gonorrhea, Chlamydia) Market (by Region), SOM, $Million, 2021-2030
Figure 239:   Northeast Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
Figure 240:   Northeast Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
Figure 241:   Northeast Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SOM, $Million, 2021-20300
Figure 242:   Midwest Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
Figure 243:   Midwest Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
Figure 244:   Midwest Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SOM, $Million, 2021-2030
Figure 245:   South Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
Figure 246:   South Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
Figure 247:   South Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SOM, $Million, 2021-2030
Figure 248:   West Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
Figure 249:   West Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), SAM, $Million, 2021-2030
Figure 250:   West Region Sexually Transmitted Infections (Syphilis, Gonorrhea, Chlamydia) Market (by State), TAM, $Million, 2021-2030
Figure 251:   U.S. Herpes Simplex Virus (HSV) Market, $Million, 2021-2030
Figure 252:   U.S. Herpes Simplex Virus (HSV) Market (by Region), TAM, $Million, 2021-2030
Figure 253:   U.S. Herpes Simplex Virus (HSV) Market (by Region), SAM, $Million, 2021-2030
Figure 254:   U.S. Herpes Simplex Virus (HSV) Market (by Region), SOM, $Million, 2021-2030
Figure 255:   Northeast Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
Figure 256:   Northeast Region Northeast Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
Figure 257:   Northeast Region Northeast Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
Figure 258:   Midwest Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
Figure 259:   Midwest Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
Figure 260:   Midwest Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
Figure 261:   South Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
Figure 262:   South Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
Figure 263:   South Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
Figure 264:   West Region Herpes Simplex Virus (HSV) Market (by State), TAM, $Million, 2021-2030
Figure 265:   West Region Herpes Simplex Virus (HSV) Market (by State), SAM, $Million, 2021-2030
Figure 266:   West Region Herpes Simplex Virus (HSV) Market (by State), SOM, $Million, 2021-2030
Figure 267:   U.S. Hepatitis Market, $Million, 2021-2030
Figure 268:   U.S. Hepatitis Market (by Region), TAM, $Million, 2021-2030
Figure 269:   U.S. Hepatitis Market (by Region), SAM, $Million, 2021-2030
Figure 270:   U.S. Hepatitis Market (by Region), SOM, $Million, 2021-2030
Figure 271:   Northeast Region Hepatitis Market (by State), TAM, $Million, 2021-2030
Figure 272:   Northeast Region Hepatitis Market (by State), SAM, $Million, 2021-2030
Figure 273:   Northeast Region Hepatitis Market (by State), SOM, $Million, 2021-2030
Figure 274:   Midwest Region Hepatitis Market (by State), TAM, $Million, 2021-2030
Figure 275:   Midwest Region Hepatitis Market (by State), SAM, $Million, 2021-2030
Figure 276:   Midwest Region Hepatitis Market (by State), SOM, $Million, 2021-2030
Figure 277:   South Region Hepatitis Market (by State), TAM, $Million, 2021-2030
Figure 278:   South Region Hepatitis Market (by State), SAM, $Million, 2021-2030
Figure 279:   South Region Hepatitis Market (by State), SOM, $Million, 2021-2030
Figure 280:   West Region Hepatitis Market (by State), TAM, $Million, 2021-2030
Figure 281:   West Region Hepatitis Market (by State), SAM, $Million, 2021-2030
Figure 282:   West Region Hepatitis Market (by State), SOM, $Million, 2021-2030
Figure 283:   U.S. Vaginal Infections Market, $Million, 2021-2030
Figure 284:   U.S. Vaginal Infections Market (by Region), TAM, $Million, 2021-2030
Figure 285:   U.S. Vaginal Infections Market (by Region), SAM, $Million, 2021-2030
Figure 286:   U.S. Vaginal Infections Market (by Region), SOM, $Million, 2021-2030
Figure 287:   Northeast Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
Figure 288:   Northeast Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
Figure 289:   Northeast Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
Figure 290:   Midwest Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
Figure 291:   Midwest Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
Figure 292:   Midwest Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
Figure 293:   South Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
Figure 294:   South Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
Figure 295:   South Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
Figure 296:   West Region Vaginal Infections Market (by State), TAM, $Million, 2021-2030
Figure 297:   West Region Vaginal Infections Market (by State), SAM, $Million, 2021-2030
Figure 298:   West Region Vaginal Infections Market (by State), SOM, $Million, 2021-2030
Figure 299:   U.S. Obstetrics and Gynecology Market (by Region), TAM, $Million, 2021-2030
Figure 300:   U.S. Obstetrics and Gynecology Market (by Region), SAM, $Million, 2021-2030
Figure 301:   U.S. Obstetrics and Gynecology Testing (by Region), SOM, $Million, 2021-2030
Figure 302:   Northeast Region Obstetrics and Gynecology Market (by State), TAM, $Million, 2021-2030
Figure 303:   Northeast Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
Figure 304:   Northeast Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
Figure 305:   Midwest Region Obstetrics and Gynecology (by State), TAM, $Million, 2021-2030
Figure 306:   Midwest Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
Figure 307:   Midwest Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
Figure 308:   South Region Obstetrics and Gynecology Market (by State), TAM, $Million, 2021-2030
Figure 309:   South Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
Figure 310:   South Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030
Figure 311:   West Region Obstetrics and Gynecology Market (by State), TAM, $Million, 2021-2030
Figure 312:   West Region Obstetrics and Gynecology Market (by State), SAM, $Million, 2021-2030
Figure 313:   West Region Obstetrics and Gynecology Market (by State), SOM, $Million, 2021-2030

Market Report Coverage

U.S. Women Health Laboratory Testing Market
Base Year	2021	Market Size in 2021	$72.8 Billion
Forecast Period	2022-2030	Value Projection and Estimation by 2030	$106.8 Billion
CAGR During Forecast Period	4.30%	Number of Tables	11
Number of Pages	231	Number of Figures	313

How can this report add value to an organization?

Segments: The different segment of the report helps the reader understand the different type of laboratory tests/services for women's health available in the market. Moreover, the study provides the reader with a detailed understanding of tests/services that fall under the different segments, which are hereditary cancer, carrier screening, prenatal screening, and diagnostic testing, reproductive health and infectious diseases, and obstetrics and gynecology.

Growth/Marketing Strategy: The U.S. women health laboratory testing market has witnessed major development by key players operating in the market, such as product launches, business expansions, partnerships, collaborations, merger and acquisitions, funding activities, and regulatory and legal approvals. The favored strategy for the companies has been regulatory and legal activities to strengthen the position of their product in the U.S. market. For instance, in October 2019, Myriad Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) approved myChoice CDx for use as a companion diagnostic for Treatment with Zejula in Late-line Ovarian Cancer.

Industry and Technology Overview

U.S. Women Health Laboratory Testing Market Industry Overview

The U.S. women health laboratory testing market was valued at $72.8 billion in 2021 and is anticipated to reach $106.8 billion by 2030, witnessing a CAGR of 4.30% during the forecast period 2022-2030. The market is driven by factors such as the increase in the prevalence of infectious diseases and cancer in women, rising awareness regarding women health-related tests, the rising average maternal age leading to increased risk of fetal chromosomal aneuploidies, and the upsurge in reproductive health problems leading to increased demand for laboratory testing in women.

Market Lifecycle Stage

The U.S. women health laboratory testing market is in the developed phase. The advancements in diagnostic technologies including applications of genetic testing in women's health and the significant number of mergers and acquisitions of companies to attain a better market share are some of the major opportunities in the U.S. women health laboratory testing market.

Figure: U.S. Women Health Laboratory Testing Market, Market Size and Forecast, 2021, 2022, and 2030

Market Segmentation:

Segmentation 1: by Hereditary Cancer
•   Breast Cancer
•   Cervical Cancer
•   Ovarian Cancer

The U.S. women health laboratory testing market (hereditary cancer) is expected to be dominated by the cervical cancer segment.

Segmentation 2: by Prenatal Screening and Diagnostic Testing
•   Non-Invasive Prenatal Testing (NIPT)
•   Maternal Serum Screening (MSS)
•   Prenatal Diagnostic Testing

The U.S. women health laboratory testing market (prenatal screening and diagnostic testing) is dominated by the non-invasive prenatal testing segment.

Segmentation 3: by Reproductive Health and Infectious Diseases
•   Pregnancy and Ovulation Testing
•   HPV Testing
•   PAP Smear Testing
•   HIV Testing
•   CT/NG Testing
•   Preimplantation Genetic Testing (PGT)
•   Sexually Transmitted Infections
•   Herpes Simplex Virus (HSV)
•   Hepatitis
•   Vaginal Infections

The U.S. women health laboratory testing market (reproductive health and infectious diseases) is dominated by the HIV testing segment.

Segmentation 4: by Region
•   Northeast Region
•   Midwest Region
•   South Region
•   West Region

The U.S. women health laboratory testing market (by region) is dominated by the South region segment.

Recent Developments in the U.S. Women Health Laboratory Testing Market

•   In November 2022, Roche Holdings launched its Cobas 5800, a new molecular diagnostic system to expand access to PCR testing in the U.S. The system can assist in the diagnosis of Infectious diseases, such as HIV, Hepatitis, transplant-associated viral illnesses, and respiratory and STIs.
•   In February 2022, the Laboratory Corporation of America Holdings established a strategic partnership with Ascension to expand its testing capabilities.
•   In January 2022, Yourgene announced that it has signed a strategic partnership agreement with EKF Diagnostics Holdings plc a point-of-care business with accredited laboratory testing capabilities in the U.S.
•   In November 2022, Myriad Genetics announced that it has acquired Gateway Genomics, LLC, a personal genomics company and developer of consumer genetic tests.
•   In August 2022, Natera, Inc. announced that the company has proactively filed a pre-submission to the FDA for its Panorama non-invasive prenatal test (NIPT) as part of the Q-Sub process.
•   In August 2021, the Laboratory Corporation of America Holdings acquired Ovia Health, to extend its leadership in women’s health.
•   In August 2021, Myriad Genetics expanded access to genetic testing by launching a new version of its market-leading MyRisk Hereditary Cancer Test

Demand – Drivers and Limitations

The following are the drivers for the U.S. Women Health Laboratory Testing Market:

•   Increase in the Prevalence of Infectious Diseases and Cancer in Women Leads to Increased Demand for Diagnosis
•   Rising Awareness Regarding Women Health-Related Tests
•   Rising Average Maternal Age Leading to Increasing Risk of Fetal Chromosomal Aneuploidies
•   Upsurge in Reproductive Health Problems Leads to Increased Demand for Laboratory Testing in Women

The market is expected to face some limitations as well due to the following challenges:

• Stringent Regulatory Guidelines Related to Laboratory Testing Hindering the Market Growth in the U.S.
• Disparity in Awareness of Pregnancy and Fertility Issues in the Different Regions of the U.S.

Analyst’s Thoughts

To emphasize the potential of the U.S. women health laboratory testing market, Swati Sood, Principal Analyst – BIS Research, states, “Women's health varies from that of men in many distinctive ways. There has been a constant increase in different diseases in women in the U.S. which leads to severe consequences. The timely diagnosis/testing of a disease is important for getting equitable management and treatment for the disease. Therefore, the significant increase in the prevalence of certain infectious diseases such as human papillomavirus (HPV), human immunodeficiency virus (HIV), HSV, hepatitis, chlamydia, gonorrhea, syphilis, and other sexually transmitted diseases and cancer in women in the U.S. over the past few years has led to an increased demand for laboratory testing, thus driving the growth of the U.S. women health laboratory testing market.”

U.S. Women Health Laboratory Testing Market - A Region-Wise Analysis

Focus on U.S. Women Health Laboratory Testing Market - Analysis and Forecast, 2022-2030

Get Free Sample

Schedule a Call

Some Faq's

Frequently Asked Questions

As per BIS Research. The U.S. women health laboratory testing market refers to the U.S. market of laboratory testing of women samples for testing disorders/diseases/infections that occur in women such as breast cancer, ovarian cancer, and Sexually Transmitted Diseases (STDs) in women such as chlamydia. It also includes pregnancy-related tests and those tests that happen during prenatal development.

The U.S. women health laboratory testing market has witnessed major developments by key players operating in the market, such as business expansions, partnerships, collaborations, regulatory and legal activities, funding activities, product launches, and acquisitions and mergers. According to BIS Research analysis, most of the companies preferred regulatory and legal activities to further increase their growth in the U.S. women health laboratory testing market. Companies such as Becton, Dickinson and Company, DiaSorin S.p.A., Roche Holdings, Myriad Genetics, and Natera Inc. have majorly adopted regulatory and legal activities as their preferred strategy.

A new entrant can focus on developing early detection tests for hereditary cancer and prenatal screening and diagnostic testing.

The following can be considered some of the USPs of the report:

· The report provides information regarding several laboratory tests for different conditions related to women, such as hereditary tests, carrier screening, prenatal screening and diagnostic testing, and reproductive health and infectious diseases.

· Drivers, Restraints, and Opportunities for the market

· Epidemiological data for each cancer type in women

· State-wise data for pregnancy rates in the U.S.

· Market numbers for each segment based on different regions in the U.S. (Northeast region, Midwest region, South region, and West region)

· TAM (total addressable market), SAM (current total market served or captured by all companies combined together), and SOM (the portion of SAM that can be realistically captured by a company in short term (3 Years)) market numbers for each segment and sub-segment

The companies developing, manufacturing, and commercializing testing products or services for U.S. women health laboratory testing market should buy this report.

A quick peek into the report

Table of Contents

Market Report Coverage

How can this report add value to an organization?

Industry and Technology Overview

$5250

U.S. Women Health Laboratory Testing Market - A Region-Wise Analysis

Frequently Asked Questions

U.S. Women Health Laboratory Testing Market - A Region-Wise Analysis

A quick peek into the report

Table of Contents

1 Markets

2 U.S. Women Health Laboratory Testing Market (by Hereditary Cancer)

3 U.S. Women Health Laboratory Testing Market (by Carrier Screening)

4 U.S. Women Health Laboratory Testing Market (by Prenatal Screening and Diagnostic Testing)

5 U.S. Women Health Laboratory Testing Market (by Reproductive Health and Infectious Diseases)

6 U.S. Women Health Laboratory Testing Market (by Obstetrics and Gynaecology)

List of Tables

List of Figures

Market Report Coverage

How can this report add value to an organization?

Industry and Technology Overview

$5250

U.S. Women Health Laboratory Testing Market - A Region-Wise Analysis

Frequently Asked Questions

Q: What is women health laboratory testing?

Q: What kinds of new strategies are being adopted by the existing market players to strengthen their market position in the industry?

Q: For a new company looking to enter the U.S. women health laboratory testing market, which areas could it focus on to stay ahead of the competition?

Q: What is the USP of this report?

Q: Who should buy this report?